Heterogeneity of genetic pathways toward daptomycin nonsusceptibility in Staphylococcus aureus determined by adjunctive antibiotics

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 5, 2015, Pages 2799-2806

  Berti, Andrew D ^a   Baines, Sarah L ^b,c   Howden, Benjamin P ^b,c,d   Sakoulas, George ^e   Nizet, Victor ^e   Proctor, Richard A ^f   Rose, Warren E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HEALTH   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; CLARITHROMYCIN; COTRIMOXAZOLE; CYTOCHROME C; DAPTOMYCIN; LINEZOLID; LIPOTEICHOIC ACID; OXACILLIN; RNA POLYMERASE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN;

ADJUVANT THERAPY; AMINO ACID SEQUENCE; ARTICLE; BACTERIAL GENETICS; BACTERIAL MEMBRANE; COMPARATIVE STUDY; DNA MODIFICATION; DRUG DETERMINATION; GENE INSERTION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; IN VITRO STUDY; INDEL MUTATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL; STOP CODON; DRUG EFFECTS; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DAPTOMYCIN; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS;

EID: 84931292153     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04990-14     Document Type: Article

References (41)

1. Gasch O, Camoez M, Domínguez MA, Padilla B, Pintado V, Almirante B, Martín C, López-Medrano F, de Gopegui ER, Blanco JR, García-Pardo G, Calbo E, Montero M, Granados A, Jover A, Dueñas C, Pujol M, REIPI/GEIH study groups. 2014. Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin. J Antimicrob Chemother 69:568-571. http://dx.doi.org/10.1093/jac/dkt396.
2. Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ. 2010. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob Agents Chemother 54:4329-4334. http://dx.doi.org/10.1128/AAC.00455-10.
3. Traunmüller F, Schintler MV, Metzler J, Spendel S, Mauric O, Popovic M, Konz KH, Scharnagl E, Joukhadar C. 2010. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother 65:1252-1257. http://dx.doi.org/10.1093/jac/dkq109.
4. Howden BP, McEvoy CR, Allen DL, Chua K, Gao W, Harrison PF, Bell J, Coombs G, Bennett-Wood V, Porter JL, Robins-Browne R, Davies JK, Seemann T, Stinear TP. 2011. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog 7:e1002359. http://dx.doi.org/10.1371/journal.ppat.1002359.
5. Mishra NN, Bayer AS, Moise PA, Yeaman MR, Sakoulas G. 2012. Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients. J Infect Dis 206:1160-1167. http://dx.doi.org/10.1093/infdis/jis482.
6. Patel D, Husain M, Vidaillac C, Steed ME, Rybak MJ, Seo SM, Kaatz GW. 2011. Mechanisms of in vitro-selected daptomycin nonsusceptibility in Staphylococcus aureus. Int J Antimicrob Agents 38:442-446. http://dx.doi.org/10.1016/j.ijantimicag.2011.06.010.
7. Bayer AS, Schneider T, Sahl HG. 2013. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci 1277:139-158. http://dx.doi.org/10.1111/j.1749-6632.2012.06819.x.
8. Peleg AY, Miyakis S, Ward DV, Earl AM, Rubio A, Cameron DR, Pillai S, Moellering RC, Eliopoulos GM. 2012. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One 7:e28316. http://dx.doi.org/10.1371/journal.pone.0028316.
9. Cui L, Isii T, Fukuda M, Ochiai T, Neoh HM, Camargo IL, Watanabe Y, Shoji M, Hishinuma T, Hiramatsu K. 2010. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob Agents Chemother 54:5222-5233. http://dx.doi.org/10.1128/AAC.00437-10.
10. Jones T, Yeaman MR, Sakoulas G, Yang SJ, Proctor RA, Sahl HG, Schrenzel J, Xiong YQ, Bayer AS. 2008. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 52:269-278. http://dx.doi.org/10.1128/AAC.00719-07.
11. Mishra NN, Rubio A, Nast CC, Bayer AS. 2012. Differential adaptations of methicillin-resistant Staphylococcus aureus to serial in vitro passage in daptomycin: evolution of daptomycin resistance and role of membrane carotenoid content and fluidity. Int J Microbiol 2012:683450.
12. Friedman L, Alder JD, Silverman JA. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 50:2137-2145. http://dx.doi.org/10.1128/AAC.00039-06.
13. Gould IM, Miró JM, Rybak MJ. 2013. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents 42:202-210. http://dx.doi.org/10.1016/j.ijantimicag.2013.05.005.
14. Kelesidis T, Humphries R, Ward K, Lewinski MA, Yang OO. 2011. Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia. Diagn Microbiol Infect Dis 71:286-290. http://dx.doi.org/10.1016/j.diagmicrobio.2011.07.001.
15. Berti AD, Wergin JE, Girdaukas GG, Hetzel SJ, Sakoulas G, Rose WE. 2012. Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics. Antimicrob Agents Chemother 56:5046-5053. http://dx.doi.org/10.1128/AAC.00502-12.
16. Reference deleted.
17. th informational supplement M100-S20. CLSI, Wayne, PA.
18. Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. Nat Methods 9:357-359. http://dx.doi.org/10.1038/nmeth.1923.
19. Cafiso V, Bertuccio T, Purrello S, Campanile F, Mammina C, Sartor A, Raglio A, Stefani S. 2014. dltA overexpression: a strain-independent keystone of daptomycin resistance in methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 43:26-31. http://dx.doi.org/10.1016/j.ijantimicag.2013.10.001.
20. Gasch O, Pillai S, Dakos J, Miyakis S, Moellering R, Eliopoulos G. 2013. Daptomycin in vitro activity against methicillin-resistant Staphylococcus aureus is enhanced by D-cycloserine in a mechanism associated with a decrease in cell surface charge. Antimicrob Agents Chemother 57:4537-4539. http://dx.doi.org/10.1128/AAC.00799-13.
21. Mehta S, Singh C, Plata KB, Chanda PK, Paul A, Riosa S, Rosato RR, Rosato AE. 2012. β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother 56:6192-6200. http://dx.doi.org/10.1128/AAC.01525-12.
22. Bayer AS, Mishra NN, Sakoulas G, Nonejuie P, Nast CC, Pogliano J, Chen KT, Ellison SN, Yeaman MR, Yang SJ. 2014. Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides. Antimicrob Agents Chemother 58:7462-7467. http://dx.doi.org/10.1128/AAC.03422-14.
23. Ernst CM, Peschel A. 2011. Broad-spectrum antimicrobial peptide resistance by MprF-mediated aminoacylation and flipping of phospholipids. Mol Microbiol 80:290-299. http://dx.doi.org/10.1111/j.1365-2958.2011.07576.x.
24. Landick R, Stewart J, Lee DN. 1990. Amino acid changes in conserved regions of the beta-subunit of Escherichia coli RNA polymerase alter transcription pausing and termination. Genes Dev 4:1623-1636. http://dx.doi.org/10.1101/gad.4.9.1623.
25. García-López MC, Navarro F. 2011. RNA polymerase II conserved protein domains as platforms for protein-protein interactions. Transcription 2:193-197. http://dx.doi.org/10.4161/trns.2.4.16786.
26. Davlieva M, Zhang W, Arias CA, Shamoo Y. 2013. Biochemical characterization of cardiolipin synthase mutations associated with daptomycin resistance in enterococci. Antimicrob Agents Chemother 57:289-296. http://dx.doi.org/10.1128/AAC.01743-12.
27. Yang SJ, Xiong YQ, Boyle-Vavra S, Daum R, Jones T, Bayer AS. 2010. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob Agents Chemother 54:3161-3169. http://dx.doi.org/10.1128/AAC.00487-10.
28. Martin PK, Li T, Sun D, Biek DP, Schmid MB. 1999. Role in cell permeability of an essential two-component system in Staphylococcus aureus. J Bacteriol 181:3666-3673.
29. Ernst CM, Staubitz P, Mishra NN, Yang SJ, Hornig G, Kalbacher H, Bayer AS, Kraus D, Peschel A. 2009. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog 5:e1000660. http://dx.doi.org/10.1371/journal.ppat.1000660.
30. Haines TH, Dencher NA. 2002. Cardiolipin: a proton trap for oxidative phosphorylation. FEBS Lett 528:35-39. http://dx.doi.org/10.1016/S0014-5793(02)03292-1.
31. Mohedano ML, Overweg K, de la Fuente A, Reuter M, Altabe S, Mulholland F, de Mendoza D, López P, Wells JM. 2005. Evidence that the essential response regulator YycF in Streptococcus pneumoniae modulates expression of fatty acid biosynthesis genes and alters membrane composition. J Bacteriol 187:2357-2367. http://dx.doi.org/10.1128/JB.187.7.2357-2367.2005.
32. Nadrah K, Strle F. 2011. Antibiotic combinations with daptomycin for treatment of Staphylococcus aureus infections. Chemother Res Pract 2011:619321. http://dx.doi.org/10.1155/2011/619321.
33. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Wang G, Sakoulas G. 2011. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 53:158-163. http://dx.doi.org/10.1093/cid/cir340.
34. Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, Rybak MJ, Kullar R, Dhand A, Rose WE, Goff DA, Bressler AM, Lee Y, Pogliano J, Johns S, Kaatz GW, Ebright JR, Nizet V. 2014. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther 36:1317-1333. http://dx.doi.org/10.1016/j.clinthera.2014.05.061.
35. Moise PA, Amodio-Groton M, Rashid M, Lamp KC, Hoffman-Roberts HL, Sakoulas G, Yoon MJ, Schweitzer S, Rastogi A. 2013. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment. Antimicrob Agents Chemother 57:1192-1200. http://dx.doi.org/10.1128/AAC.02192-12.
36. rd Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
37. Komatsuzawa H, Ohta K, Fujiwara T, Choi GH, Labischinski H, Sugai M. 2001. Cloning and sequencing of the gene, fmtC, which affects oxacillin resistance in methicillin-resistant Staphylococcus aureus. FEMS Microbiol Lett 203:49-54. http://dx.doi.org/10.1111/j.1574-6968.2001.tb10819.x.
38. Peschel A, Jack RW, Otto M, Collins LV, Staubitz P, Nicholson G, Kalbacher H, Nieuwenhuizen WF, Jung G, Tarkowski A, van Kessel KP, van Strijp JA. 2001. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine. J Exp Med 193:1067-1076. http://dx.doi.org/10.1084/jem.193.9.1067.
39. Yang SJ, Mishra NN, Rubio A, Bayer AS. 2013. Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance. Antimicrob Agents Chemother 57:5658-5664. http://dx.doi.org/10.1128/AAC.01184-13.
40. Rubio A, Conrad M, Haselbeck RJ, Kedar GC, Brown-Driver V, Finn J, Silverman JA. 2011. Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus. Antimicrob Agents Chemother 55:364-367. http://dx.doi.org/10.1128/AAC.00429-10.
41. Berti AD, Sakoulas G, Nizet V, Tewhey R, Rose WE. 2013. β-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 57:5005-5012. http://dx.doi.org/10.1128/AAC.00594-13.